Tech Company Financing Transactions
Sight Sciences Funding Round
Sight Sciences secured a $30 million Series E investment round on 3/19/2020. Investors included D1 Capital Partners and private investors.
Transaction Overview
Company Name
Announced On
3/19/2020
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series E
Investors
D1 Capital Partners (Lead Investor) (James Rogers)
Proceeds Purpose
Proceeds will be used for continued clinical and operational development and to support commercial expansion for Sight Sciences' OMNI and TearCare products.
Company Information
Company Status
Publicly-held
Industry
Medical Devices & Instruments
Mailing Address
4040 Campbell Ave. 100
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Website
Email Address
Overview
Sight Sciences, Inc. is a privately held ophthalmic medical device company whose mission is to revolutionize how we think about and treat the leading causes of eye disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Badawi
Chief Financial Officer
Jesse Selnick
Chief Medical Officer
Reay Brown
Chief Technical Officer
David Badawi
Vice President
Jessica Holmes
Vice President
Chris Pike
Vice President
Richard Rush
VP - Bus. Development
Shawn O'Neil
VP - Manufacturing
John Ordway
VP - Marketing
Todd Love
VP - Marketing
James Sluck
VP - Marketing
Patrick Smale
VP - R & D
Daniel O'Keeffe
VP - Regulatory Affairs
Ingrid Kane
VP - Sales
Aaron Capsel
VP - Sales
Jeffrey Francis
Browse more venture capital transactions:
Prev: 3/19/2020: Attestiv venture capital transaction
Next: 3/19/2020: VXG venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We document all VC transactions involving tech companies. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs